| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7910131 | SUPERNUS PHARMS | Method of treating seizures using modified release formulations of oxcarbazepine |
Apr, 2027
(2 years from now) | |
| US9119791 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US9370525 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US10220042 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US9855278 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US11166960 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US8821930 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US9351975 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US8617600 | SUPERNUS PHARMS | Modified release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
| US7722898 | SUPERNUS PHARMS | Modified-release preparations containing oxcarbazepine and derivatives thereof |
Apr, 2027
(2 years from now) | |
Oxtellar Xr is owned by Supernus Pharms.
Oxtellar Xr contains Oxcarbazepine.
Oxtellar Xr has a total of 10 drug patents out of which 0 drug patents have expired.
Oxtellar Xr was authorised for market use on 19 October, 2012.
Oxtellar Xr is available in tablet, extended release;oral dosage forms.
Oxtellar Xr can be used as treatment of partial-onset seizures.
The generics of Oxtellar Xr are possible to be released after 13 April, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 19, 2015 |
Drugs and Companies using OXCARBAZEPINE ingredient
Market Authorisation Date: 19 October, 2012
Treatment: Treatment of partial-onset seizures
Dosage: TABLET, EXTENDED RELEASE;ORAL
OXTELLAR XR family patents
